Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 30,800 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $19.38, for a total value of $596,904.00. Following the sale, the chief executive officer now directly owns 725,951 shares in the company, valued at $14,068,930.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Atara Biotherapeutics Inc (NASDAQ:ATRA) traded up 5.99% during mid-day trading on Monday, reaching $21.25. The company’s stock had a trading volume of 376,992 shares. The firm’s 50 day moving average is $16.27 and its 200-day moving average is $17.10. The stock’s market cap is $618.14 million. Atara Biotherapeutics Inc has a one year low of $12.45 and a one year high of $25.73.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, March 9th. The company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.98) by $0.35. Equities analysts expect that Atara Biotherapeutics Inc will post ($3.70) earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Alyeska Investment Group L.P. increased its position in shares of Atara Biotherapeutics by 0.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 408,200 shares of the company’s stock worth $5,796,000 after buying an additional 3,254 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Atara Biotherapeutics by 37.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,797 shares of the company’s stock worth $310,000 after buying an additional 5,883 shares during the last quarter. BlackRock Inc. increased its position in shares of Atara Biotherapeutics by 108.1% in the third quarter. BlackRock Inc. now owns 12,697 shares of the company’s stock worth $272,000 after buying an additional 6,597 shares during the last quarter. Eagle Asset Management Inc. increased its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares during the last quarter. Finally, Elkfork Partners LLC acquired a new position in shares of Atara Biotherapeutics during the fourth quarter worth approximately $135,000. 77.48% of the stock is owned by hedge funds and other institutional investors.
ATRA has been the topic of several research reports. Jefferies Group LLC set a $23.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Monday, December 12th. Canaccord Genuity set a $47.00 price objective on Atara Biotherapeutics and gave the company a “buy” rating in a research report on Saturday, March 11th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 4th. Finally, Citigroup Inc set a $10.00 price objective on Atara Biotherapeutics and gave the company a “sell” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $24.00.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.